Show
Sort by
-
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics : 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study
-
- Journal Article
- A1
- open access
IL-23 and axial disease : do they come together?
-
- Journal Article
- A1
- open access
Axial involvement in psoriatic arthritis cohort (AXIS) : the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
-
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V) : 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
-
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR) : results from a randomised, placebo-controlled, phase 2 trial
-
- Journal Article
- A1
- open access
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force
-
Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis : results from a randomised phase III trial (FUTURE 1)
-
- Journal Article
- A1
- open access
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis
-
Better performance of the Leeds and Sparcc enthesitis indices compared to the mases in patients with peripheral spondyloarthritis during treatment with adalimumab
-
- Journal Article
- A1
- open access
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force